ClinicalTrials.gg
CompletedNCT00363480Updated Mar 9, 2018Results posted

Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data

A Phase 4 interventional study of Salmeterol/Fluticasone 50/250 mcg and Salbutamol 100 mcg in Asthma, sponsored by GlaxoSmithKline. Completed at 32 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-09.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
221
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 72 studies testing albuterol in Asthma — 8 open to participants now, 9 under way, 1 of them phase 3. Albuterol · Asthma.

Enrollment
13th of 72
221 · median 63
Started
2006
with 3 others
Phase 4
25 of 72
2 open now
Registered
5th of 72
by date
Lead sponsor
8 of 72
GlaxoSmithKline

Among the 72 studies testing albuterol in Asthma, this one is the 13th largest by enrollment, is one of 4 that started in 2006, is one of 25 in phase 4, and was the 5th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

8 of the 72 studies testing albuterol in Asthma are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies testing albuterol in Asthma, or all of them as a file.
02

Study summary

The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Seretide (salmeterol/fluticasone combination, SFC) 50/250 µg twice daily. The asthma control test (ACT) will be used to detect differences in the level of asthma control during treatment. The study aims to show a correlation between improvements of ACT und the level of asthma control which will be reached by the patients.

The aim of the study is to show that most of symptomatic asthma patients can reach 'well controlled asthma' with SFC. We get information about ACT in daily practice and physicians are trained to use the asthma control test as a screening tool and for follow up of asthma management. Correlations are expected between the improvements in ACT, Quality of Life and asthma control according to the Gaining Optimal Asthma controL (GOAL) criteria.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Asthma Control Test
  • SERETIDE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of asthma
  • Reversibility >12% after inhalation of 200 µg Salbutamol
  • willingness and ability to complete daily record card on daily basis and to measure morning PEF on daily basis
  • 80% compliance in diary card completion asthma control status: Uncontrolled based on the GOAL criteria

Exclusion criteria

Exclusion criteria:

  • Change of asthma medication during the last 4 weeks
  • Asthma exacerbation characterized by use of oral corticoids during the last 3 months Pretreatment with inhaled more than 500 mcg Beclometasondipropionat or equivalent per day or other controller therapy during the last 3 months
  • upper or lower respiratory tract infection during the RUN-IN period moderate or severe asthma exacerbation during the RUN-IN period
  • Non compliance with use of Discus, PEF-meter and incomplete diary card data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    SFC 50/250 mcg

    Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.

    Drug: Salmeterol/Fluticasone 50/250 mcg · Drug: Salbutamol 100 mcg · Device: DISKUS™ powder inhalers

Interventions

  • DrugSalmeterol/Fluticasone 50/250 mcg

    Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.

  • This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.

  • DeviceDISKUS™ powder inhalers

    Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.

06

What researchers measure

Primary outcomes

  1. Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12

    A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score \>1 (Range: 0= None to 5= severe), rescue salbutamol use on \<= 2 days and at most 4 occasions per week, and a morning peak flow \>= 80% of the predicted value on each day per week. All of the criteria which includes no night-time awakenings due to asthma (diary entry), no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change are fulfilled. The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control.

    Time frame: Week 9 to Week 12

Secondary outcomes

  1. Change From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12

    The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. In order to derive the total ACT score, all 5 questions needed to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Time frame: Baseline (Visit 3) and Week 12

  2. Change From Baseline in Mean ACT Score at Visit 6

    The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms not under control. In order to derive the total ACT score, all 5 questions had to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Time frame: Baseline (Viait 3) and Week 12

  3. Number of Participants With Well Controlled and Totally Controlled Asthma at Week 12

    Well controlled or totally controlled asthma assessments were done according to the GOAL criteria. A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score \>1(Range: 0= None to 5= severe), rescue salbutamol use on \<= 2 days and at most 4 occasions per week, and morning peak flow \>= 80% of the predicted value on each day per week. All of the criteria which included no night-time awakenings due to asthma (diary entry),no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change were fulfilled. The total ACT score was based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Time frame: Week 12

  4. Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)

    For the level of asthma control, baseline values were derived taking the last 8 weeks during the pre-treatment period prior to Visit 3 into consideration. Regarding derived variables based on the asthma diary, data from the last week prior to Visit 3 was taken. Visit 3, regarded as baseline. AQLQ has 32 questions regarding activities, emotions, symptoms, and environmental triggers. Each item values range from 1 (maximum impairment) to 7 (no impairment). A positive change from baseline score indicates improvement.

    Time frame: Baseline (Visit 3) up to Week 12

  5. Correlation of Change in AQLQ Score and Change in ACT Score

    Correlation between change in the AQLQ and ACT score was tabulated using the Pearson coefficient of correlation (linear correlation). The AQLQ contained 32 items in 4 domains: activity limitation, symptoms, emotional function and environmental stimuli. Scores for the domains as well as the overall score were scaled within a range of 1 (worst) to 7 (best).

    Time frame: Week 12

  6. Change From Baseline in Forced Expiratory Volume (FEV1) to Week 12

    FEV1, an amount of air exhaled by a person during a forced breath in one second. FEV1 assessed at Visit 1 and at Visits 3, 4, 5, 6. Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.

    Time frame: Baseline (Visit 3) up to Week 12

  7. Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12

    PEF, a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. The mean morning PEF evaluated by means of the data documented in the asthma diaries. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Time frame: Baseline (Visit 3) and Week 12

  8. Change From Baseline in Mean 24-hour Symptom Score at Week 12

    The various symptoms like wheezing, shortness of breath, coughing and chest tightness were assessed by the participants every morning using a symptom score scale which ranged from 0 (no symptoms during the past 24 hours) to 5 (symptoms so severe that participant could not go to work or carry out other normal daily activities). Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Time frame: Baseline (Visit 3) and Week 12

  9. Change From Baseline in Number of Additional Usage of Salbutamol at Week 12

    Salbutamol was given as a rescue medicine, used on \<= 2 days and at most 4 occasions per week. Change from baseline value was calculated by subtracting the baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Time frame: Baseline (Visit 3) and week 12

  10. Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12

    Number of nights with no night time awakening were recorded at Week 12. Baseline was the last corresponding time period immediately prior to Visit 3.

    Time frame: Baseline (Visit 3) and week 12

  11. Number of Participants With Emergency Visits Due to Asthma

    Frequencies of emergency visits per participant were recorded during treatment period. Only the participants at risk were considered when calculating the incidence rates.

    Time frame: Up to week 12

  12. Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment

    AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with AE who lead to change in asthma treatment were reported.

    Time frame: Up to Week 12

  13. Assessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE

    An AE is any untoward medical occurrence in a participant or clinical AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with at least one treatment emergent serious and, non-serious AE were reported.

    Time frame: Up to Week 12

  14. Assessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP were recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.

    Time frame: Baseline (Visit 3) up to Week 12

  15. Assessment of Tolerability by Change From Baseline of Pulse Rate

    Pulse rate was recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.

    Time frame: Baseline (Visit 3) up to Week 12

  16. Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements

    Frequencies of participants with at least one (near-) incident associated with peak flow measurements were recorded. analysis was done on safety population.

    Time frame: Up to Week 12

07

Results

Posted Mar 9, 2018

Participant flow

Study was conducted at 27 centers in Germany from 17 May 2006 to 6 September 2007 on participants diagnosed with perennial bronchial asthma.

Participant flow — Overall Study
MilestoneSFC 50/250 mcg
Started221
Completed204
Not completed17
Withdrew: Criteria for treatment period not fulfil1
Withdrew: Adverse event4
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject5
Withdrew: Non-compliance of subject1
Withdrew: Participant discontinued on its own1

Outcome measures

PrimaryPercentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12

A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score \>1 (Range: 0= None to 5= severe), rescue salbutamol use on \<= 2 days and at most 4 occasions per week, and a morning peak flow \>= 80% of the predicted value on each day per week. All of the criteria which includes no night-time awakenings due to asthma (diary entry), no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change are fulfilled. The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control.

Time frame:
Week 9 to Week 12
Reported as:
Number · Percentage
Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12
PercentageSFC 50/250 mcg
GOAL33.5
ACT64.1
Statistical analysis
  • SFC 50/250 mcg · McNemar · p = <0.0001 · Percentage diffrence: -30.6 · 95% CI -37.89 to -23.29
SecondaryChange From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12

The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. In order to derive the total ACT score, all 5 questions needed to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

Time frame:
Baseline (Visit 3) and Week 12
Reported as:
Number · Participants
Change From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12
ParticipantsSFC 50/250 mcg
Baseline32
Week 12139
Statistical analysis
  • SFC 50/250 mcg · T-distribution: 50.2 · 95% CI 43.15 to 57.32
SecondaryChange From Baseline in Mean ACT Score at Visit 6

The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms not under control. In order to derive the total ACT score, all 5 questions had to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

Time frame:
Baseline (Viait 3) and Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in Mean ACT Score at Visit 6
Score on a scaleSFC 50/250 mcg
Change From Baseline in Mean ACT Score at Visit 65.0 ± 4.3
SecondaryNumber of Participants With Well Controlled and Totally Controlled Asthma at Week 12

Well controlled or totally controlled asthma assessments were done according to the GOAL criteria. A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score \>1(Range: 0= None to 5= severe), rescue salbutamol use on \<= 2 days and at most 4 occasions per week, and morning peak flow \>= 80% of the predicted value on each day per week. All of the criteria which included no night-time awakenings due to asthma (diary entry),no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change were fulfilled. The total ACT score was based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

Time frame:
Week 12
Reported as:
Number · Participants
Number of Participants With Well Controlled and Totally Controlled Asthma at Week 12
ParticipantsSFC 50/250 mcg
Well Controlled65 (23 to 36)
Totally Controlled29
SecondaryChange From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)

For the level of asthma control, baseline values were derived taking the last 8 weeks during the pre-treatment period prior to Visit 3 into consideration. Regarding derived variables based on the asthma diary, data from the last week prior to Visit 3 was taken. Visit 3, regarded as baseline. AQLQ has 32 questions regarding activities, emotions, symptoms, and environmental triggers. Each item values range from 1 (maximum impairment) to 7 (no impairment). A positive change from baseline score indicates improvement.

Time frame:
Baseline (Visit 3) up to Week 12
Reported as:
Mean · Score on Scale
Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)
Score on ScaleSFC 50/250 mcg
Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)0.83 ± 0.91
SecondaryCorrelation of Change in AQLQ Score and Change in ACT Score

Correlation between change in the AQLQ and ACT score was tabulated using the Pearson coefficient of correlation (linear correlation). The AQLQ contained 32 items in 4 domains: activity limitation, symptoms, emotional function and environmental stimuli. Scores for the domains as well as the overall score were scaled within a range of 1 (worst) to 7 (best).

Time frame:
Week 12
Reported as:
Number · participants
Correlation of Change in AQLQ Score and Change in ACT Score
participantsSFC 50/250 mcg
Correlation of Change in AQLQ Score and Change in ACT Score0.522
SecondaryChange From Baseline in Forced Expiratory Volume (FEV1) to Week 12

FEV1, an amount of air exhaled by a person during a forced breath in one second. FEV1 assessed at Visit 1 and at Visits 3, 4, 5, 6. Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.

Time frame:
Baseline (Visit 3) up to Week 12
Reported as:
Mean · Litre/second (L/Sec)
Change From Baseline in Forced Expiratory Volume (FEV1) to Week 12
Litre/second (L/Sec)SFC 50/250 mcg
Week 40.133 ± 0.320
Week 80.212 ± 0.359
Week 120.181 ± 0.372
SecondaryChange From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12

PEF, a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. The mean morning PEF evaluated by means of the data documented in the asthma diaries. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

Time frame:
Baseline (Visit 3) and Week 12
Reported as:
Mean · Percentage
Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12
PercentageSFC 50/250 mcg
Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 127.798 ± 10.302
SecondaryChange From Baseline in Mean 24-hour Symptom Score at Week 12

The various symptoms like wheezing, shortness of breath, coughing and chest tightness were assessed by the participants every morning using a symptom score scale which ranged from 0 (no symptoms during the past 24 hours) to 5 (symptoms so severe that participant could not go to work or carry out other normal daily activities). Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

Time frame:
Baseline (Visit 3) and Week 12
Reported as:
Mean · Score on Scale
Change From Baseline in Mean 24-hour Symptom Score at Week 12
Score on ScaleSFC 50/250 mcg
Change From Baseline in Mean 24-hour Symptom Score at Week 12-0.590 ± 0.948
SecondaryChange From Baseline in Number of Additional Usage of Salbutamol at Week 12

Salbutamol was given as a rescue medicine, used on \<= 2 days and at most 4 occasions per week. Change from baseline value was calculated by subtracting the baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

Time frame:
Baseline (Visit 3) and week 12
Reported as:
Mean · Number of occassions
Change From Baseline in Number of Additional Usage of Salbutamol at Week 12
Number of occassionsSFC 50/250 mcg
Change From Baseline in Number of Additional Usage of Salbutamol at Week 12-0.933 ± 1.331
SecondaryPercent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12

Number of nights with no night time awakening were recorded at Week 12. Baseline was the last corresponding time period immediately prior to Visit 3.

Time frame:
Baseline (Visit 3) and week 12
Reported as:
Mean · Percent Change
Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12
Percent ChangeSFC 50/250 mcg
Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 127.228 ± 24.921
SecondaryNumber of Participants With Emergency Visits Due to Asthma

Frequencies of emergency visits per participant were recorded during treatment period. Only the participants at risk were considered when calculating the incidence rates.

Time frame:
Up to week 12
Reported as:
Number · Participants
Number of Participants With Emergency Visits Due to Asthma
ParticipantsSFC 50/250 mcg
At least 1 day13
1 day10
2 days2
3-4 days1
5-9 days0
SecondaryNumber of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment

AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with AE who lead to change in asthma treatment were reported.

Time frame:
Up to Week 12
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment
ParticipantsSFC 50/250 mcg
Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment4
SecondaryAssessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE

An AE is any untoward medical occurrence in a participant or clinical AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with at least one treatment emergent serious and, non-serious AE were reported.

Time frame:
Up to Week 12
Reported as:
Number · Participants
Assessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE
ParticipantsSFC 50/250 mcg
Any Non-Serious AE76
Any Serious AE1
SecondaryAssessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.

Time frame:
Baseline (Visit 3) up to Week 12
Reported as:
Mean · millimeters of mercury (mmHg)
Assessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
millimeters of mercury (mmHg)SFC 50/250 mcg
SBP, Week 40.8 ± 12.7
SBP, Week 8-0.7 ± 11.3
SBP, Week 120.2 ± 13.5
DBP, Week 40.2 ± 8.8
DBP, Week 8-0.2 ± 8.4
DBP, Week 120.6 ± 9.0
SecondaryAssessment of Tolerability by Change From Baseline of Pulse Rate

Pulse rate was recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.

Time frame:
Baseline (Visit 3) up to Week 12
Reported as:
Mean · Beats per minute (bpm)
Assessment of Tolerability by Change From Baseline of Pulse Rate
Beats per minute (bpm)SFC 50/250 mcg
Week 41.0 ± 9.0
Week 8-0.2 ± 9.1
Week 120.6 ± 10.2
SecondaryNumber of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements

Frequencies of participants with at least one (near-) incident associated with peak flow measurements were recorded. analysis was done on safety population.

Time frame:
Up to Week 12
Reported as:
Number · participants
Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements
participantsSFC 50/250 mcg
Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements0

Adverse events

Collected over Up to Week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SFC 50/250 mcg1/221 (0.5%)1/221 (0.5%)76/221 (34.4%)
Most frequent serious events
Most frequent serious events
EventSFC 50/250 mcg
Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/221
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/221
Most frequent other events
Showing 10 of 50
Most frequent other events
EventSFC 50/250 mcg
HeadacheNervous system disorders23/221
NasopharyngitisInfections and infestations18/221
BronchitisInfections and infestations12/221
AsthmaRespiratory, thoracic and mediastinal disorders8/221
Respiratory tract infectionInfections and infestations6/221
SinusitisInfections and infestations6/221
Back painMusculoskeletal and connective tissue disorders5/221
Pain in extremityMusculoskeletal and connective tissue disorders4/221
ToothacheGastrointestinal disorders3/221
ArthralgiaMusculoskeletal and connective tissue disorders3/221

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SFC 50/250 mcg
Mean49.5 ± 15.5
Sex: Female, Male
Sex: Female, Male(Participants)SFC 50/250 mcg
Female142
Male79
08

Study locations

32 sites
  • GSK Investigational Site
    Erlangen, Bayern 91052, Germany
  • GSK Investigational Site
    Kaufbeuren, Bayern 87600, Germany
  • GSK Investigational Site
    Landsberg, Bayern 86899, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80335, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81677, Germany
  • GSK Investigational Site
    Rednitzhembach, Bayern 91126, Germany
  • GSK Investigational Site
    Uttenreuth, Bayern 91080, Germany
  • GSK Investigational Site
    Wuerzburg, Bayern 97070, Germany
  • GSK Investigational Site
    Cottbus, Brandenburg 03050, Germany
  • GSK Investigational Site
    Wedel, Hamburg 22880, Germany
  • GSK Investigational Site
    Bad Arolsen, Hessen 34454, Germany
  • GSK Investigational Site
    Eschwege, Hessen 37269, Germany
  • GSK Investigational Site
    Kassel, Hessen 34117, Germany
  • GSK Investigational Site
    Kassel, Hessen 34121, Germany
  • GSK Investigational Site
    Marburg, Hessen 35037, Germany
  • GSK Investigational Site
    Braunschweig, Niedersachsen 38100, Germany
  • GSK Investigational Site
    Buchholz, Niedersachsen 21244, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30167, Germany
  • GSK Investigational Site
    Chemnitz, Sachsen 09126, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01099, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Greiz, Thueringen 07973, Germany
  • GSK Investigational Site
    Sonneberg, Thueringen 96515, Germany
  • GSK Investigational Site
    Berlin, 10367, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10965, Germany
  • GSK Investigational Site
    Berlin, 12165, Germany
  • GSK Investigational Site
    Berlin, 12687, Germany
  • GSK Investigational Site
    Berlin, 13187, Germany
  • GSK Investigational Site
    Berlin, 13597, Germany
  • GSK Investigational Site
    Hamburg, 22767, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2006 to primary completion in Sep 2007, 15 months.

Results were first posted in Mar 2018, 10 years 6 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 15 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2006
First posted
Aug 15, 2006
StartActual
May 17, 2006
Primary completionActual
Sep 1, 2007
CompletionActual
Sep 14, 2007
Results first posted
Mar 9, 2018
Last update
Mar 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00363480
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 15, 2006
Start date
May 17, 2006
Primary completion
Sep 1, 2007
Completion
Sep 14, 2007
Results posted
Mar 9, 2018
Last update
Mar 9, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albuterol

Start the discussion